Ozempic Gastroparesis Settlement: Claim Valuation Factors Overview

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Risk Awareness

For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge. This legacy of providing accessible health information has empowered individuals to make informed decisions about their well-being. As medical science advances, the focus naturally shifts from general awareness to specific, real-world applications of new therapies. The introduction of GLP-1 receptor agonists, such as Ozempic, represents a significant evolution in managing metabolic conditions. However, with widespread clinical adoption comes the responsibility to understand the full spectrum of patient experiences. The transition from general health education to a more targeted concern involves recognizing that pharmaceutical interventions, while beneficial for many, may carry unintended consequences for some individuals. This pivot requires examining how exposure to these medications correlates with emerging patient-reported outcomes. The conversation now moves from abstract health principles to a concrete examination of risk factors associated with Ozempic use, particularly regarding gastrointestinal function. This shift acknowledges that the same compounds designed to improve metabolic health may, in certain populations, be linked to conditions requiring careful medical and legal consideration. The following analysis focuses on the valuation factors relevant to claims involving gastroparesis potentially associated with Ozempic exposure.

Find Out If You Qualify for Compensation →

The Medical and Legal Nexus: Ozempic and Gastroparesis

The association between Ozempic (semaglutide) and gastroparesis is a subject of increasing medical and legal scrutiny. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presents clinically with symptoms such as nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The pharmacological mechanism of Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, includes slowing gastric motility as part of its glucose-lowering effect, which can exacerbate or unmask gastroparesis in susceptible individuals. Clinical trial data from the Ozempic prescribing information indicate a significantly higher incidence of gastrointestinal adverse reactions compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was also more common with Ozempic (3.1% for 0.5 mg and 3.8% for 1 mg) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal reactions with a frequency below 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Post-Marketing Evidence and Risk Context

Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) further highlight the association. Among adverse-event reports most frequently associated with Ozempic, "impaired gastric emptying" appears with 2,693 reports, alongside nausea (8,652 reports), vomiting (5,578 reports), and dyspepsia (1,374 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). These reports provide real-world evidence of the mechanistic link between Ozempic and delayed gastric emptying, which can progress to clinically significant gastroparesis. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a central consideration. The prescribing information lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct condition. The label notes that nausea, vomiting, and diarrhea occur most frequently during dose escalation, but it does not address the potential for persistent or severe gastric emptying impairment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may be relevant in settlement-related considerations, as patients who developed gastroparesis after Ozempic use may argue that the risks were not adequately communicated.

Claim Valuation Factors in Ozempic Gastroparesis Settlements

Settlement valuation for Ozempic-related gastroparesis claims typically factors in several elements: the severity and duration of symptoms, the need for medical interventions such as dietary modifications, prokinetic medications, or gastric electrical stimulation, and the impact on quality of life. The timeline between exposure to Ozempic and documented harm is also critical. In clinical trials, gastrointestinal adverse reactions often emerged during dose escalation, but post-marketing reports suggest that impaired gastric emptying can occur at any point during treatment (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). Claims may be stronger when there is a clear temporal relationship, such as symptom onset within weeks to months of starting Ozempic, and when alternative causes (e.g., diabetes-related gastroparesis, prior surgery) are excluded. Other valuation factors include the strength of the mechanistic evidence. GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting vagal nerve activity and reducing antral contractions, which can directly contribute to gastroparesis. The FAERS data, with thousands of reports of impaired gastric emptying, support this pathway (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). However, the overall incidence of gastroparesis in Ozempic users is not precisely quantified, and confounding factors such as underlying diabetes (which itself can cause gastroparesis) may complicate causation. In settlement negotiations, defendants may argue that the label adequately warns of gastrointestinal effects, while plaintiffs may contend that the specific risk of gastroparesis was downplayed. The frequency of gastrointestinal adverse reactions in trials (up to 36.4%) and the high number of FAERS reports for impaired gastric emptying (2,693) provide a factual basis for claims (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166; https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). Ultimately, each claim is evaluated on its individual merits, including medical records, expert testimony, and the specific timeline of exposure and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric motility as part of its mechanism. Clinical trials show a significantly higher incidence of gastrointestinal adverse reactions compared to placebo, and post-marketing data from FAERS include thousands of reports of impaired gastric emptying, which can progress to gastroparesis. The prescribing information does not explicitly warn of gastroparesis as a distinct condition, which may be relevant in legal claims.

What factors are considered in valuing an Ozempic gastroparesis claim?

Key factors include the severity and duration of symptoms, need for medical interventions (e.g., dietary changes, prokinetics, gastric stimulation), impact on quality of life, temporal relationship between Ozempic exposure and symptom onset, exclusion of alternative causes, and the strength of mechanistic evidence. The high incidence of gastrointestinal adverse reactions in trials and FAERS reports provide factual support for claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.